Transforming the
standard of care

Therapies targeting initial immune responses have the potential to
prevent pathologic inflammation from initiating versus neutralizing
downstream inflammatory responses and mediators (akin to stopping
a fire from starting versus having to put it out). We believe this
approach differentiates us from current therapies targeting adaptive
immune responses, which suppress inflammation only after it occurs.
These current treatment options have produced meaningful benefits to
patients but share fundamental limitations due to cytokine redundancy
—blocking one target cytokine does not prevent others from driving
chronic inflammation.

By focusing on upstream immune responses, our product candidates
have the potential, whether as monotherapies or in combination, to
address the issue of downstream cytokine redundancy and mitigate
direct damage caused by the innate immune response, while having
less immunosuppressive risk.